Picture of Eris Lifesciences logo

ERIS — Eris Lifesciences News Story

0.000.00%
in flag iconLast trade - 00:00
HealthcareBalancedMid CapFalling Star

India's Biocon posts Q1 profit rise on sale of branded formulations business

HYDERABAD, Aug 8 (Reuters) - Biopharmaceutical company
Biocon Ltd  BION.NS  reported a more than six-fold rise in
first-quarter profit on Thursday, boosted by a one-time gain
from the sale of its Indian branded formulations business. 
    Biocon said in March it would sell the branded formulations
business to Eris Lifesciences  ERIS.NS  in a deal worth 12.42
billion rupees. 
    "Transaction has come into effect on April 1,2024... Gain of
10.57 billion rupees is accounted after taking into account
working capital and expenses incurred towards commercial
collaboration," Biocon said. 
    The company, which counts the United States and Europe as
key markets, posted a net profit attributable to shareholders of
6.6 billion rupees ($78.62 million) for the quarter ended June
30, compared with 1.01 billion rupees a year earlier.
    The company's quarterly profit was also boosted by the
increased market share of its biosimilars, which include
treatments for cancer, diabetes and immunology-related
conditions.
    Biocon had invested more than $1 billion rupees in its
biosimilars unit and acquired businesses globally to compete in
the market expected to triple in value to $74 billion by the end
of the decade. 
    Revenue from its biosimilars segment rose 3.4% to 20.83
billion rupees from a year ago.
    However, revenue from its generics segment fell 5.9% to 6.6
billion rupees, hurt by pricing pressure in the U.S. market.
    The company's shares closed 2.2% lower on Thursday, ahead of
the results.


($1 = 83.9460 Indian rupees)

 (Reporting by Rishika  Sadam; Editing by Eileen Soreng and
Shreya Biswas)
 ((Rishika.Sadam@thomsonreuters.com;))

Recent news on Eris Lifesciences

See all news